Biomarker-directed therapy for pancreatic cancer

Michael J. Pishvaian; Jonathan R. Brody

doi:10.1016/B978-0-12-800684-9.00001-0

Biomarker-directed therapy for pancreatic cancer

Michael J. Pishvaian, Jonathan R. Brody

Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, and soon will be the second leading cause of cancer-related death in the United States. Chemotherapy has improved outcomes for patients with PDAC, but the median overall survival remains only about 1 year. However, multiple recent studies evaluating the mutational landscape of PDAC have revealed that up to 25% of patient tumors harbor “actionable” mutations—that is, mutations that predict for a high rate of response with appropriately targeted therapy. Herein, we describe the most actionable molecular abnormalities in PDAC, and evaluate the clinical trial experience with appropriately matched therapies. We consider how subdividing PDAC into multiple small biomarker-based subgroups provides a glimpse into the future infrastructure of how precision medicine might work for the treatment of this deadly disease.

Original language	English (US)
Title of host publication	Genomic and Precision Medicine
Subtitle of host publication	Oncology, Third Edition
Publisher	Elsevier
Pages	239-254
Number of pages	16
ISBN (Electronic)	9780128006849
ISBN (Print)	9780128006535
DOIs	https://doi.org/10.1016/B978-0-12-800684-9.00001-0
State	Published - Jan 1 2022

Keywords

Pancreatic cancer
actionable mutations
pancreatic ductal adenocarcinoma
precision medicine
sequencing
targeted therapy

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/B978-0-12-800684-9.00001-0

Cite this

@inbook{1a31633711d14f6e8e0ebd730833f4e8,

title = "Biomarker-directed therapy for pancreatic cancer",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, and soon will be the second leading cause of cancer-related death in the United States. Chemotherapy has improved outcomes for patients with PDAC, but the median overall survival remains only about 1 year. However, multiple recent studies evaluating the mutational landscape of PDAC have revealed that up to 25% of patient tumors harbor “actionable” mutations—that is, mutations that predict for a high rate of response with appropriately targeted therapy. Herein, we describe the most actionable molecular abnormalities in PDAC, and evaluate the clinical trial experience with appropriately matched therapies. We consider how subdividing PDAC into multiple small biomarker-based subgroups provides a glimpse into the future infrastructure of how precision medicine might work for the treatment of this deadly disease.",

keywords = "Pancreatic cancer, actionable mutations, pancreatic ductal adenocarcinoma, precision medicine, sequencing, targeted therapy",

author = "Pishvaian, {Michael J.} and Brody, {Jonathan R.}",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-800684-9.00001-0",

language = "English (US)",

isbn = "9780128006535",

pages = "239--254",

booktitle = "Genomic and Precision Medicine",

publisher = "Elsevier",

}

TY - CHAP

T1 - Biomarker-directed therapy for pancreatic cancer

AU - Pishvaian, Michael J.

AU - Brody, Jonathan R.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, and soon will be the second leading cause of cancer-related death in the United States. Chemotherapy has improved outcomes for patients with PDAC, but the median overall survival remains only about 1 year. However, multiple recent studies evaluating the mutational landscape of PDAC have revealed that up to 25% of patient tumors harbor “actionable” mutations—that is, mutations that predict for a high rate of response with appropriately targeted therapy. Herein, we describe the most actionable molecular abnormalities in PDAC, and evaluate the clinical trial experience with appropriately matched therapies. We consider how subdividing PDAC into multiple small biomarker-based subgroups provides a glimpse into the future infrastructure of how precision medicine might work for the treatment of this deadly disease.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, and soon will be the second leading cause of cancer-related death in the United States. Chemotherapy has improved outcomes for patients with PDAC, but the median overall survival remains only about 1 year. However, multiple recent studies evaluating the mutational landscape of PDAC have revealed that up to 25% of patient tumors harbor “actionable” mutations—that is, mutations that predict for a high rate of response with appropriately targeted therapy. Herein, we describe the most actionable molecular abnormalities in PDAC, and evaluate the clinical trial experience with appropriately matched therapies. We consider how subdividing PDAC into multiple small biomarker-based subgroups provides a glimpse into the future infrastructure of how precision medicine might work for the treatment of this deadly disease.

KW - Pancreatic cancer

KW - actionable mutations

KW - pancreatic ductal adenocarcinoma

KW - precision medicine

KW - sequencing

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85137874467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137874467&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800684-9.00001-0

DO - 10.1016/B978-0-12-800684-9.00001-0

M3 - Chapter

AN - SCOPUS:85137874467

SN - 9780128006535

SP - 239

EP - 254

BT - Genomic and Precision Medicine

PB - Elsevier

ER -

Biomarker-directed therapy for pancreatic cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this